Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the role of glasdegib in acute myeloid leukemia (AML), which was approved by the FDA for older patients unfit for intensive chemotherapy. Despite the approval of this agent, Dr Short explains that the combination of azacitidine and venetoclax explored in the VIALE-A trial (NCT02993523) demonstrated better response rates in patients, and is therefore more commonly used than combinations with glasdegib. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.